Rosenstock, Julio

Impact of a weekly glucagon-like peptide 1 receptor agonist, albiglutide, on glycemic control and on reducing prandial insulin use in type 2 diabetes inadequately controlled on multiple insulin therapy: a randomized trial.

Rosenstock, J., Nino, A., Soffer, J., Erskine, L., Acusta, A., Dole, J., Carr, M. C., Mallory, J., & Home, P. (2020) · Diabetes Care

Diabetes Treatment and ManagementDiabetes Management and Research

Cited by 73

Advancing therapy in suboptimally controlled basal insulin-treated type 2 diabetes: Clinical outcomes with iGlarLixi versus premix BIAsp 30 in the SoliMix randomized controlled trial

Rosenstock, J., Emral, R., Sauque-Reyna, L., Mohan, V., Trescolí, C., Al Sifri, S., Lalic, N., Alvarez, A., Picard, P., Bonnemaire, M., et al. (2021) · Diabetes Care

Diabetes Treatment and ManagementDiabetes Management and Research

Cited by 63

Effects of linagliptin on cardiovascular and kidney outcomes in people with normal and reduced kidney function: secondary analysis of the CARMELINA randomized trial

Perkovic, V., Toto, R., Cooper, M. E., Mann, J. F. E., Rosenstock, J., McGuire, D. K., Kahn, S. E., Marx, N., Alexander, J. H., Zinman, B., et al. (2020) · Diabetes Care

Diabetes Treatment and ManagementChronic Kidney Disease and Diabetes

Cited by 62

Achieving Normoglycemia With Tirzepatide: Analysis of SURPASS 1–4 Trials

Rosenstock, J., Vázquez, L., Del Prato, S., Franco, D. R., Weerakkody, G., Dai, B., Landó, L. F., Bergman, B. K., & Rodríguez, A. (2023) · Diabetes Care

Diabetes Treatment and ManagementDiabetes Management and Research

Cited by 45

Efficacy and safety of canagliflozin used in conjunction with sulfonylurea in patients with type 2 diabetes mellitus: a randomized, controlled trial

Fulcher, G., Matthews, D. R., Perkovic, V., de Zeeuw, D., Mahaffey, K. W., Weiss, R., Rosenstock, J., Capuano, G., Desai, M., Shaw, W., et al. (2015) · Diabetes Therapy

Diabetes Treatment and ManagementDiabetes Management and Research

Cited by 44

Inhaled Technosphere Insulin versus inhaled technosphere placebo in insulin-naïve subjects with type 2 diabetes inadequately controlled on oral antidiabetes agents

Rosenstock, J., Franco, D., Korpachev, V., Shumel, B., Ma, Y., Baughman, R., Amin, N., McGill, J. B., & for the Affinity 2 Study Group (2015) · Diabetes Care

Diabetes Treatment and ManagementDiabetes Management and Research

Cited by 43

Treatment with orforglipron, an oral glucagon-like peptide-1 receptor agonist, is associated with improvements of CV risk biomarkers in participants with type 2 diabetes or obesity without diabetes

Wharton, S., Rosenstock, J., Konige, M., Lin, Y., Duffin, K., Wilson, J., Banerjee, H., Pirro, V., Kazda, C., & Mather, K. (2025) · Cardiovascular Diabetology

Diabetes Treatment and ManagementDiabetes, Cardiovascular Risks, and Lipoproteins

Cited by 26

Reduced glucose variability with glucose-dependent versus glucose-independent therapies despite similar glucose control and hypoglycemia rates in a randomized, controlled study of older patients with type 2 diabetes mellitus

Pratley, R. E., Rosenstock, J., Heller, S. R., Sinclair, A., Heine, R. J., Kiljański, J., Brusko, C. S., Duan, R., & Festa, A. (2018) · Journal of Diabetes Science and Technology

Diabetes Treatment and ManagementDiabetes Management and Research

Cited by 13

P2857Increase in pulse rate with semaglutide did not result in increased adverse cardiac events in subjects with type 2 diabetes in the SUSTAIN 6 cardiovascular outcomes trial

Seufert, J., Nauck, M., Rosenstock, J., Hansen, T., Vrazic, H., & Vilsboll, T. (2018) · European Heart Journal

Diabetes Treatment and ManagementBlood Pressure and Hypertension Studies

Cited by 9

SEMAGLUTIDE REDUCES HIGH-SENSITIVITY CRP LEVELS ACROSS DIFFERENT TREATMENT FORMULATIONS: EXPLORATORY ANALYSES OF SUSTAIN 3 AND PIONEER 1, 2 AND 5 TRIALS

Rosenstock, J., Capehorn, M., De Remigis, A., Rasmussen, S., Weimers, P., & Mosenzon, O. (2021) · Journal of the American College of Cardiology

Diabetes Treatment and ManagementLipoproteins and Cardiovascular Health

Cited by 6

Weight Loss Maintenance With Once-Weekly Semaglutide 2.4 MG in Adults With Overweight or Obesity Reaching Maintenance Dose (STEP 4)

Rubino, D. M., Abrahamsson, N., Davies, M., Hesse, D., Greenway, F. L., Jensen, C., Lingvay, I., Mosenzon, O., Rosenstock, J., Rubio, M. A., et al. (2021) · Journal of the Endocrine Society

Pharmacology and Obesity TreatmentDiabetes Treatment and Management

Cited by 3